Loading...
Market
Success Rate of Initial CRISPR Clinical Trials by 2027
5
Resolution / Starting Odds
Below 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
Above 75% • 25%
Clinical trial results published in medical journals or press releases from Regeneron and Mammoth Biosciences
Story
Regeneron Invests $100M in Mammoth for CRISPR-Based Gene Editing Therapies
Apr 25, 2024, 11:30 AM
Regeneron Pharmaceuticals has announced a significant expansion into gene editing by partnering with Mammoth Biosciences. The collaboration aims to research, develop, and commercialize CRISPR-based gene editing therapies for various diseases, targeting multiple tissues and cell types. Regeneron will make a substantial financial commitment, including a $5 million upfront payment and a $95 million equity investment in the CRISPR startup, totaling $100 million. This move is part of Regeneron's broader strategy to deepen its capabilities in genetic medicines, including a recent acquisition in cell therapy and ongoing partnerships focused on developing treatments for rare diseases like transthyretin amyloidosis. Mammoth, which previously developed CRISPR technology for COVID-19 diagnostics, has shifted focus to smaller DNA-cutting enzymes that could be more easily delivered into tissues across the body.
View original story
Similar markets
Yes, for one therapy • 40%
Yes, for more than one therapy • 20%
No • 40%
Approval • 33%
Request for additional data • 33%
Rejection • 33%
Cancer • 25%
Alzheimer's Disease • 25%
Cystic Fibrosis • 25%
Sickle Cell Disease • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
More than 20 • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Transthyretin Amyloidosis • 25%
Sickle Cell Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
1-2 diseases • 33%
3-4 diseases • 33%
5 or more diseases • 33%
Below 50% • 25%
50% to 75% • 25%
75% to 90% • 25%
Above 90% • 25%